The combined targeting of the LAG-3 and PD-1 pathways on anti-cancer efficacy raises the possibility that these two ICPs are co-expressed on anergic T cells and work together to facilitate cancer immune evasion [46]. This evidence concerns the gene LAG3 and cancer.